The mission of the MMRC is to champion collaboration with and integration across academia and industry and to focus on speed and innovation to bring the most promising multiple myeloma treatments to patients faster.
The MMRC is comprised of 16 Member Institutions nationwide that form its clinical trials network. It is led by an Executive Committee in Norwalk, Connecticut, and a Steering Committee and Progress Review Committee comprised of researchers from MMRC Member Institutions. The MMRC also includes a shared Tissue Bank to advance clinical trials and correlative science studies conducted through the MMRC's clinical trials network and the Multiple Myeloma Genomics Initiative.
The MMRC is focused on advancing Phase I and Phase II clinical trials of novel compounds and combination approaches. To date, the MMRC has advanced more than 30 clinical trials with partners, including Novartis, Celgene, Merck, and Proteolix at record speed. MMRC clinical trials are also designed to include correlative studies to better understand what drugs are most effective in treating various sub-groups of patients with myeloma, laying the foundation for the development of personalized medicine.
For more information, contact the MMRF.